
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is a promising company with a diversified portfolio of products in Phase 2 trials, including ALTO-207 which is expected to be the primary driver of share price appreciation. While there are third party and commercial risks involved, the company's promising early evidence in depressive disorders makes it an interesting investment opportunity with a strong cash position to support its endeavors. However, the recent ALTO-101 program's failure to meet primary endpoints and subsequent deprioritization may impact the company's valuation and future partnerships.
Bears say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a risky outlook due to the high failure rates of clinical trials in depression and the unproven nature of its biomarker approach. The company also faces financial risks and third party risks, and its valuation is complex and reliant on forward assumptions. With the company needing to raise additional capital and its lead asset not expected to have top-line results until 2H27, there is potential for share dilution and uncertainty surrounding the success of its pipeline. Additionally, competition from established companies and potential competitors in the market could impact the company's success.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares